Androgen Receptors Act as a Tumor Suppressor Gene to Suppress Hepatocellular Carcinoma Cells Progression via miR-122-5p/RABL6 Signaling

Hepatocellular carcinoma (HCC) is a malignant tumor with a high degree of malignancy and a poor prognosis. Androgen receptor (AR) has been reported to play important roles in the regulation of the progression of HCC, but the underlying mechanisms of how AR regulates HCC initiation, progression, meta...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 756779
Main Authors Tang, Neng, Dou, Xiaolin, You, Xing, Li, Yixiong, Li, Xi, Liu, Guodong
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 20.10.2021
Subjects
androgen receptor
hepatocellular carcinoma
invasion
microRNA
migration
Oncology
migration
microRNA
androgen receptor
invasion
hepatocellular carcinoma
Online AccessGet full text

Cover

More Information
Summary:Hepatocellular carcinoma (HCC) is a malignant tumor with a high degree of malignancy and a poor prognosis. Androgen receptor (AR) has been reported to play important roles in the regulation of the progression of HCC, but the underlying mechanisms of how AR regulates HCC initiation, progression, metastasis, and chemotherapy resistance still need further study. Our study found that AR could act as a tumor suppression gene to suppress HCC cells invasion and migration capacities miR-122-5p/RABL6 signaling, and the mechanism study further confirmed that miR-122-5p could suppress the expression of RABL6 to influence HCC cells progression by directly targeting the 3'UTR of the mRNA of RABL6. The preclinical study using an mouse model with orthotopic xenografts of HCC cells confirmed the data, and the clinical data gotten from online databases based on TCGA samples also confirmed the linkage of AR/miR-122-5p/RABL6 signaling to the HCC progression. Together, these findings suggest that AR could suppress HCC invasion and migration capacities miR-122-5p/RABL6 signaling, and targeting this newly explored signaling may help us find new therapeutic targets for better treatment of HCC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Yin-Yuan Mo, University of Mississippi Medical Center, United States
Reviewed by: Xiujun Cai, Sir Run Run Shaw Hospital, China; Amrita Sule, Yale University, United States
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.756779